Postrock Partners LLC Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS)

Postrock Partners LLC acquired a new position in Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 12,309 shares of the medical research company’s stock, valued at approximately $692,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Huntington National Bank boosted its holdings in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC bought a new position in Exact Sciences in the third quarter worth about $34,000. Asset Planning Inc acquired a new position in Exact Sciences in the fourth quarter valued at approximately $40,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences during the 4th quarter worth approximately $43,000. Finally, AlphaQuest LLC lifted its holdings in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after purchasing an additional 913 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Down 7.1 %

NASDAQ:EXAS opened at $43.04 on Friday. The stock’s 50-day moving average is $52.26 and its two-hundred day moving average is $59.06. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a market cap of $7.99 billion, a PE ratio of -7.73 and a beta of 1.25. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EXAS has been the subject of a number of analyst reports. Piper Sandler reduced their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. BTIG Research boosted their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Barclays decreased their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Finally, Bank of America cut their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $70.83.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.